Long-term growth hormone therapy in an adolescent boy with 45,X/46,XidicY(p11).
A 17-year-old boy with chromosomal mosaicism resulting in a 45,X/46,X,idic(Y)(p11) karyotype came to medical attention at the age of 10 years because of short stature. He was treated with recombinant growth hormone for 6.6 years and has achieved a near final adult height of 172.5 cm. His clinical features included second-degree hypospadias, some stigmata of Turner syndrome, and spontaneous progression through puberty. We report long-term use of growth hormone in a male adolescent with isodicentric Yq.
Guevarra
Frances M
FM
Pediatric Endocrinology, Department of Pediatrics, The Mount Sinai School of Medicine, New York, NY 10029, USA.
Nimkarn
Saroj
S
New
Maria I
MI
Lin-Su
Karen
K
D000293:Adolescent; D001827:Body Height / Q000187:drug effects*; D002869:Chromosome Aberrations; D041321:Chromosomes, Human, X; D041322:Chromosomes, Human, Y; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006130:Growth Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007021:Hypospadias / Q000175:diagnosis / Q000601:surgery; D007621:Karyotyping; D008297:Male; D009634:Noonan Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
D019382:Human Growth Hormone